HYDERABAD, India – As China surges ahead in the biosimilars space, Indian biopharma companies are increasingly concerned about their ability to keep pace due to lack of policy support and pricing controls.
NEW DELHI, India – Princeton, N.J.-based Vyome Therapeutics Inc., which specializes in medicines for treating skin diseases caused by resistant microbes, has announced a $22 million financing for the phase IIb trial of its lead molecule, VB-1953, for treatment of moderate to severe acne.
NEW DELHI, India - Princeton, N.J.-based Vyome Therapeutics Inc., which specializes in medicines for treating skin diseases caused by resistant microbes, has announced a $22 million financing for the phase IIb trial of its lead molecule, VB-1953, for treatment of moderate to severe acne.
NEW DELHI – With record domestic approvals, active engagement in semi-regulated markets and a growing footprint in regulated markets, the Indian biosimilars industry is poised to hit the $40 billion mark by 2030, according to a new industry analysis report.
NEW DELHI – With record domestic approvals, active engagement in semi-regulated markets and a growing footprint in regulated markets, the Indian biosimilars industry is poised to hit the $40 billion mark by 2030, according to a new industry analysis report.
NEW DELHI – In a move that could further pave the way for Cipla Ltd., one of India's best-known makers of generics, to tap into the lucrative U.S. market, Invagen Pharmaceuticals Inc., a subsidiary of Mumbai-based Cipla, has entered a two-stage agreement to acquire the specialty hospital business of Avenue Therapeutics Inc. in the U.S.
NEW DELHI – In a move that could further pave the way for Cipla Ltd., one of India's best-known makers of generics, to tap into the lucrative U.S. market, Invagen Pharmaceuticals Inc., a subsidiary of Mumbai-based Cipla, has entered a two-stage agreement to acquire the specialty hospital business of Avenue Therapeutics Inc. in the U.S.
NEW DELHI – India's vaccine industry is limping to recovery after a number of setbacks in growth in recent months even as some industry experts worry that the domestic sector is losing ground to China and South Korea.
NEW DELHI – India's vaccine industry is limping to recovery after a number of setbacks in growth in recent months even as some industry experts worry that the domestic sector is losing ground to China and South Korea.
